A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alzheimer's disease is characterized by the presence of cortical amyloid-beta (Aβ) protein plaques, which result from the sequential action of β-secretase and γ-secretase on amyloid precursor protein. Semagacestat is a small-molecule γ-secretase inhibitor that was developed as a potential treatment for Alzheimer's disease. METHODS: We conducted a double-blind, placebo-controlled trial in which 1537 patients with probable Alzheimer's disease underwent randomization to receive 100 mg of semagacestat, 140 mg of semagacestat, or placebo daily. Changes in cognition from baseline to week 76 were assessed with the use of the cognitive subscale of the Alzheimer's Disease Assessment Scale for cognition (ADAS-cog), on which scores range from 0 to 70 and higher scores indicate greater cognitive impairment, and changes in functioning were assessed with the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale, on which scores range from 0 to 78 and higher scores indicate better functioning. A mixed-model repeated-measures analysis was used. RESULTS: The trial was terminated before completion on the basis of a recommendation by the data and safety monitoring board. At termination, there were 189 patients in the group receiving placebo, 153 patients in the group receiving 100 mg of semagacestat, and 121 patients in the group receiving 140 mg of semagacestat. The ADAS-cog scores worsened in all three groups (mean change, 6.4 points in the placebo group, 7.5 points in the group receiving 100 mg of the study drug, and 7.8 points in the group receiving 140 mg; P=0.15 and P=0.07, respectively, for the comparison with placebo). The ADCS-ADL scores also worsened in all groups (mean change at week 76, -9.0 points in the placebo group, -10.5 points in the 100-mg group, and -12.6 points in the 140-mg group; P=0.14 and P<0.001, respectively, for the comparison with placebo). Patients treated with semagacestat lost more weight and had more skin cancers and infections, treatment discontinuations due to adverse events, and serious adverse events (P<0.001 for all comparisons with placebo). Laboratory abnormalities included reduced levels of lymphocytes, T cells, immunoglobulins, albumin, total protein, and uric acid and elevated levels of eosinophils, monocytes, and cholesterol; the urine pH was also elevated. CONCLUSIONS: As compared with placebo, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability. Semagacestat was associated with more adverse events, including skin cancers and infections. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT00594568.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, participants experienced adverse reactions such as gastrointestinal symptoms, skin cancer, and infections, which are speculated to be related to the inhibition of other γ-secretase substrates, including notch, CD44, ErbB4, and cadherin.438–441”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [438]
In the citing paper
“Disappointingly, the use of γ-secretase inhibitors (GSIs) has shown limited efficacy in treating Alzheimer's disease [113].”
From The low-density lipoprotein receptor: Emerging post-transcriptional regulatory mechanisms (2025) · cites this paper as [113]
In the citing paper
“Several drugs that have shown promising results in Alzheimer mouse models have failed to prevent cognitive decline in late-phase clinical trials87–89.”
From The use of brain organoids to investigate neural development and disease (2017) · cites this paper as [88]
In the citing paper
“However, with the failures or unsatisfactory efficacy of drugs anti-Aβ [9, 208–211], the development of drugs targeting other targets is increasing, such as anti-tau pathology and anti-neuroinflammation [212].”
From Tau and neuroinflammation in Alzheimer’s disease: interplay mechanisms and clinical translation (2023) · cites this paper as [208]
In the citing paper
“Semagacestat was the first GSI to enter a phase 3 trial for AD. However, the trial was halted early due to concerns of worsening cognition, increased incidence of skin cancers and infection, and weight loss relative to placebo (Doody et al., 2013).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Doody et al., 2013
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia
Cummings, J. L., Mega, M., Gray, K., Rosenberg-Thompson, S., Carusi, D. A., & Gornbein, J. (1994) · Neurology · doi:10.1212/wnl.44.12.2308 · Cited by 7,568
An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
Galasko, D., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00005 · Cited by 1,194
Self-citationO’Bryant, S. E. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1091 · Cited by 884
Wong, G. T., Manfra, D., Poulet, F. M., Zhang, Q., Josien, H., Bara, T., Engstrom, L., Pinzon-Ortiz, M., Fine, J. S., Lee, H.-J. J., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311652200 · Cited by 718
Mohs, R. C., Knopman, D., Petersen, R. C., Ferris, S. H., Ernesto, C., Grundman, M., Sano, M., Bieliauskas, L., Geldmacher, D., Clark, C., et al. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00003 · Cited by 692
Self-citationClinical Gerontology: A Guide to Assessment and Intervention
Brink, T. L. (1986) · Medical Entomology and Zoology · Cited by 594
Geling, A., Steiner, H., Willem, M., Bally‐Cuif, L., & Haass, C. (2002) · The EMBO Reports · doi:10.1093/embo-reports/kvf124 · Cited by 497
The mechanism of γ‐Secretase dysfunction in familial Alzheimer disease
Chávez‐Gutiérrez, L., Bammens, L., Benilova, I., Vandersteen, A., Benurwar, M., Borgers, M., Lismont, S., Zhou, L., Van Cleynenbreugel, S., Esselmann, H., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.79 · Cited by 495
Research works printed but not linked: 2
- Wimo A, Wetterholm A-L, Mastey V, Winbald B. Evaluation of the healthcare resource utilization and caregiver time in anti-dementia drug trials. In: Wimo A, Jönsson B, Karlsson G, Winblad B, eds. The health economics of dementia. London: Wiley, 1998:465-99.
- Kind P. The EuroQol instrument: an index of health-related quality of life. In: Spilker B, ed. Quality of life and pharmacoeconomics in clinical trials. 2nd ed. Philadelphia: Lippincott-Raven, 1996:191-201.
Cited by
Items 201–300 of 1,002
Down syndrome: Neurobiological alterations and therapeutic targets
Vacca, R. A., Bawari, S., Valenti, D., Tewari, D., Nabavi, S. F., Shirooie, S., Sah, A. N., Volpicella, M., Braidy, N., & Nabavi, S. M. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.01.001 · Cited by 90
Treating Alzheimer's disease by targeting iron
Nikseresht, S., Bush, A. I., & Ayton, S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14567 · Cited by 98
“The γ‐secretase inhibitor, semagacestat, was shown to reduce Aβ in a Phase 2 trial (Fleisher et al., 2008); however, the Phase 3 trial was halted when an interim analysis revealed that the drug worsened cognition and increased the incidence of skin cancer (Doody et al., 2013).”
BackgroundYang, H., Li, X., Zhu, L., Wu, X., Zhang, S., Huang, F., Feng, X., & Shi, L. (2019) · Advanced Science · doi:10.1002/advs.201901844 · Cited by 98
Mullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.026 · Cited by 98
Modulation of Brain Hyperexcitability: Potential New Therapeutic Approaches in Alzheimer’s Disease
Toniolo, S., Sen, A., & Husain, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239318 · Cited by 94
Estrogen-dependent DLL1-mediated Notch signaling promotes luminal breast cancer
Kumar, S., Srivastav, R. K., Wilkes, D. W., Ross, T., Kim, S., Kowalski, J., Chatla, S., Zhang, Q. H., Nayak, A., Guha, M., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0562-z · Cited by 103
Lesions without symptoms: understanding resilience to Alzheimer disease neuropathological changes
Gómez-Isla, T., & Frosch, M. P. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00642-9 · Cited by 96
Microbiota-gut-brain axis and toll-like receptors in Alzheimer’s disease
Lin, C., Zhao, S., Zhu, Y., Fan, Z., Wang, J., Zhang, B., & Chen, Y. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.09.008 · Cited by 89
Ono, K., & Tsuji, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030952 · Cited by 92
“Other large, phase 3 trials using anti-amyloid approaches including semagacestat [18], bapineuzumab [19], and solanezumab [20], have yielded disappointing results.”
BackgroundGao, C., Chu, X., Gong, W., Zheng, J., Xie, X., Wang, Y., Yang, M., Li, Z., Gao, C., & Yang, Y. (2020) · Journal of Nanobiotechnology · doi:10.1186/s12951-020-00626-1 · Cited by 93
RetractedTreatment of Alzheimer’s Disease: Beyond Symptomatic Therapies
Buccellato, F. R., D’Anca, M., Tartaglia, G. M., Del Fabbro, M., Scarpini, E., & Galimberti, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813900 · Cited by 94
Pant, S., Jones, S. F., Kurkjian, C. D., Infante, J. R., Moore, K. N., Burris, H. A., McMeekin, D. S., Benhadji, K. A., Patel, B. K. R., Frenzel, M. J., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.021 · Cited by 92
Uwajeh, P. C., Iyendo, T. O., & Polay, M. (2019) · EXPLORE · doi:10.1016/j.explore.2019.05.002 · Cited by 116
Exosomes in neurologic and psychiatric disorders
Tsilioni, I., Panagiotidou, S., & Theoharides, T. C. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.05.005 · Cited by 93
Csiszar, A., Tarantini, S., Fülöp, G. A., Kiss, T., Valcarcel-Ares, M. N., Galvan, V., Ungvari, Z., & Yabluchanskiy, A. (2017) · GeroScience · doi:10.1007/s11357-017-9991-9 · Cited by 93
AKT-dependent NOTCH3 activation drives tumor progression in a model of mesenchymal colorectal cancer
Varga, J., Nicolas, A., Petrocelli, V., Pesic, M., Mahmoud, A., Michels, B. E., Etlioglu, E., Yepes, D., Häupl, B., Ziegler, P. K., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191515 · Cited by 93
Tsatsanis, A., Wong, B. X. W., Gunn, A. P., Ayton, S., Bush, A. I., Devos, D., & Duce, J. A. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0762-0 · Cited by 97
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer’s Disease
Liu-Seifert, H., Initiative, T. A. D. N., Siemers, E., Price, K., Han, B., Selzler, K. J., Henley, D., Sundell, K., Aisen, P., Cummings, J., et al. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142508 · Cited by 77
“The results from the IDENTITY studies have been reported previously [28].”
ResultSelf-citationOn the Role of Store-Operated Calcium Entry in Acute and Chronic Neurodegenerative Diseases
Secondo, A., Bagetta, G., & Amantea, D. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00087 · Cited by 91
“, 2017), supporting a poor association between brain amyloid-β levels and cognitive function (Doody et al., 2013; Briggs et al., 2017).”
BackgroundClioquinol rescues Parkinsonism and dementia phenotypes of the tau knockout mouse
Lei, P., Ayton, S., Appukuttan, A. T., Volitakis, I., Adlard, P. A., Finkelstein, D. I., & Bush, A. I. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.03.015 · Cited by 93
“clinical trials targeting -amyloid aggregation, a key feature of AD, were conducted, but failed to demonstrate efficiency (3-5).”
BackgroundThe Notch pathway in CNS homeostasis and neurodegeneration
Ho, D. M., Artavanis‐Tsakonas, S., & Louvi, A. (2020) · WIREs Developmental Biology · doi:10.1002/wdev.358 · Cited by 90
“Even the more specific, so-called “Notch-sparing” GSIs, such as avagacestat, can, at least in some contexts, inhibit cleavage of both Notch and APP (Chavez-Gutierrez et al., 2012).”
BackgroundInfluentialSatlin, A., Wang, J., Logovinsky, V., Berry, S., Swanson, C., Dhadda, S., & Berry, D. A. (2016) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.01.001 · Cited by 89
Brody, A. H., & Strittmatter, S. M. (2018) · Advances in Pharmacology · doi:10.1016/bs.apha.2017.09.007 · Cited by 86
“Finally, while immunotherapy with antibodies raised against Aβ has been shown to reduce plaque burden in AD patients, such interventions have failed to improve patient outcome (Doody et al., 2013, 2014; Holmes et al., 2008; Salloway et al., 2014; reviewed by Spires-Jones & Hyman, 2014).”
BackgroundThe informed road map to prevention of Alzheimer Disease: a call to arms
McDade, E., Llibre-Guerra, J. J., Holtzman, D. M., Morris, J. C., & Bateman, R. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00467-y · Cited by 89
“The approaches include Aβ active or passive immunization [33–37], and γ- and β-secretase inhibitors or modulators [10, 38, 39].”
BackgroundDietary (−)-epicatechin as a potent inhibitor of βγ-secretase amyloid precursor protein processing
Cox, C. J., Choudhry, F., Peacey, E., Perkinton, M. S., Richardson, J. C., Howlett, D. R., Lichtenthaler, S. F., Francis, P. T., & Williams, R. J. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.07.032 · Cited by 87
“…an important consideration was the potential for inhibitory actions at g-secretase as there have been a number of recent clinical trial failures for AD drugs because of off target effects at notch, leading to gastrointestinal and immune cell toxicity (Doody et al., 2013; Imbimbo et al., 2011).”
C99 selectively accumulates in vulnerable neurons in Alzheimer's disease
Pulina, M. V., Hopkins, M., Haroutunian, V., Greengard, P., & Bustos, V. (2020) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.09.002 · Cited by 85
“Semagacestat, a gamma-secretase inhibitor, worsened the symptoms of dementia in a large phase III clinical trial [29].”
Current Biomarkers for Alzheimer’s Disease: From CSF to Blood
Zou, K., Abdullah, M., & Michikawa, M. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030085 · Cited by 83
Gerber, H., Wu, F., Dimitrov, M., Garcia Osuna, G. M., & Fraering, P. C. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.754101 · Cited by 89
Sarasija, S., Laboy, J. T., Ashkavand, Z., Bonner, J., Tang, Y., & Norman, K. R. (2018) · eLife · doi:10.7554/elife.33052 · Cited by 88
Tomioka, I., Ishibashi, H., Minakawa, E. N., Motohashi, H. H., Takayama, O., Saito, Y., Popiel, H. A., Puentes, S., Owari, K., Nakatani, T., et al. (2017) · eNeuro · doi:10.1523/eneuro.0250-16.2017 · Cited by 88
“These limitations have resulted in the failure to predict the efficacy of clinical trials in human patients from the experimental findings obtained from rodent models of neurodegenerative diseases, lessening the preclinical value of rodent models (Doody et al. 2013, 2014; Salloway et al. 2014).”
BackgroundXu, T.-H., Yan, Y., Kang, Y., Jiang, Y., Melcher, K., & Xu, H. E. (2016) · Cell Discovery · doi:10.1038/celldisc.2016.26 · Cited by 83
Drug development for Alzheimer’s disease: Review
Lao, K., Ji, N., Zhang, X., Qiao, W., Tang, Z., & Gou, X. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2018.1474361 · Cited by 86
“[38] Doody RS, Raman R, Farlow M, et al.”
BackgroundCognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease
Wessels, A. M., Lines, C., Stern, R. A., Kost, J., Voss, T., Mozley, L. H., Furtek, C., Mukai, Y., Aisen, P. S., Cummings, J. L., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12164 · Cited by 86
Self-citationWessels, A. M., Siemers, E. R., Yu, P., Andersen, S. W., Holdridge, K. C., Sims, J. R., Sundell, K., Stern, Y., Rentz, D. M., Dubois, B., et al. (2015) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2015.82 · Cited by 86
Self-citationJia, Q., Deng, Y., & Qing, H. (2014) · BioMed Research International · doi:10.1155/2014/837157 · Cited by 81
“Two pivotal phase 3 trials were reluctantly started; however they were discontinued due to increased risk of skin cancer and infection and lack of efficacy [56].”
BackgroundInteractions between glial cells and the blood-brain barrier and their role in Alzheimer's disease
Zhao, M., Jiang, X., Zhang, H., Sun, J., Pei, H., Ma, L., Cao, Y., & Li, H. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101483 · Cited by 99
Alzheimer’s and ABC transporters — new opportunities for diagnostics and treatment
Pahnke, J., Langer, O., & Krohn, M. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.04.001 · Cited by 81
Pharmacogenomics of Alzheimer’s Disease: Novel Therapeutic Strategies for Drug Development
Cacabelos, R., Cacabelos, P., Torrellas, C., Tellado, I., & Carril, J. C. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0956-8_13 · Cited by 90
Signature Amyloid β Profiles Are Produced by Different γ-Secretase Complexes
Acx, H., Chávez-Gutiérrez, L., Serneels, L., Lismont, S., Benurwar, M., Elad, N., & De Strooper, B. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.530907 · Cited by 77
Therapeutic Targeting of Notch Signaling: From Cancer to Inflammatory Disorders
Allen, F., & Maillard, I. P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.649205 · Cited by 91
Wood, L. B., Winslow, A. R., Proctor, E. A., McGuone, D., Mordes, D. A., Frosch, M. P., Hyman, B. T., Lauffenburger, D. A., & Haigis, K. M. (2015) · Scientific Reports · doi:10.1038/srep16622 · Cited by 84
Panax ginseng components and the pathogenesis of Alzheimer's disease (Review)
Razgonova, M. P., Veselov, V. V., Zakharenko, A. M., Golokhvast, K. S., Nosyrev, A. E., Cravotto, G., Tsatsakis, A. M., & Spandidos, D. A. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.9972 · Cited by 131
Upregulation of RIN3 induces endosomal dysfunction in Alzheimer’s disease
Shen, R., Zhao, X., He, L., Ding, Y., Xu, W., Lin, S., Fang, S., Yang, W., Sung, K., Spencer, B., et al. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00206-1 · Cited by 75
Finding Treatment Effects in Alzheimer Trials in the Face of Disease Progression Heterogeneity
Jutten, R. J., Sikkes, S. A. M., Van der Flier, W. M., Scheltens, P., Visser, P. J., Tijms, B. M., & Initiative, F. T. A. D. N. (2021) · Neurology · doi:10.1212/wnl.0000000000012022 · Cited by 81
Two decades of new drug discovery and development for Alzheimer's disease
Liu, Z., Zhang, A., Sun, H., Han, Y., Kong, L., & Wang, X. (2017) · RSC Advances · doi:10.1039/c6ra26737h · Cited by 83
Hampel, H., Schneider, L. S., Giacobini, E., Kivipelto, M., Sindi, S., Dubois, B., Broich, K., Nisticò, R., Aisen, P. S., & Lista, S. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.995637 · Cited by 75
“The g-secretase inhibitor semagacestat [116] and the N-terminus anti-amyloid mAb bapineuzumab [73], in particular, demonstrated target engagement in the CNS yet no beneficial effect on cognition in mild-to-moderate AD.”
BackgroundSelf-citationEgan, M. F., Mukai, Y., Voss, T., Kost, J., Stone, J., Furtek, C., Mahoney, E., Cummings, J. L., Tariot, P. N., Aisen, P. S., et al. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0520-1 · Cited by 81
Self-citationPresenilin 1 and Presenilin 2 Target γ-Secretase Complexes to Distinct Cellular Compartments
Meckler, X., & Checler, F. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.708297 · Cited by 76
Panza, F., Solfrizzi, V., Imbimbo, B. P., & Logroscino, G. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.935332 · Cited by 75
Powering Amyloid Beta Degrading Enzymes: A Possible Therapy for Alzheimer’s Disease
Sikanyika, N. L., Parkington, H., Smith, A., & Kuruppu, S. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02756-x · Cited by 63
Yoo, J., Lee, J., Ahn, B., Han, J., & Lim, M. H. (2025) · Chemical Science · doi:10.1039/d4sc06762b · Cited by 80
“55,56,59 Additionally, some g -secretase inhibitors exhibited toxic e ff ects, such as an increased risk of skin cancer, likely resulted from o ff -target interactions with proteins like the Notch receptor, which is involved in cell proliferation via nuclear signaling.”
James, M. L., Belichenko, N. P., Shuhendler, A. J., Höhne, A., Andrews, L., Condon, C., Nguyen, T. V., Reiser, V., Jones, P. A., Trigg, W., et al. (2017) · Theranostics · doi:10.7150/thno.17666 · Cited by 78
Biomarker-guided decision making in clinical drug development for neurodegenerative disorders
Cummings, J. L., Teunissen, C. E., Fiske, B. K., Ber, I. L., Wildsmith, K. R., Schöll, M., Dunn, B., & Scheltens, P. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01165-w · Cited by 88
Bandyopadhyay, S., & Rogers, J. T. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.032 · Cited by 74
“The failure of anti-amyloid therapies that target γ-secretase [9] and Aβ vaccine in clinical trials has generated considerable interest in discovering safer and more effective alternatives [10].”
BackgroundWang, J., Lu, R., Yang, J., Li, H., He, Z., Jing, N., Wang, X., & Wang, Y. (2015) · Nature Communications · doi:10.1038/ncomms9876 · Cited by 79
Semagacestat Is a Pseudo-Inhibitor of γ-Secretase
Tagami, S., Yanagida, K., Kodama, T. S., Takami, M., Mizuta, N., Oyama, H., Nishitomi, K., Chiu, Y.-W., Okamoto, T., Ikeuchi, T., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.032 · Cited by 74
The intestinal microbiome and Alzheimer's disease: A review
Li, Z., Zhu, H., Zhang, L., & Qin, C. (2018) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12033 · Cited by 82
Pharmacotherapy of Alzheimer’s Disease: Seeking Clarity in a Time of Uncertainty
Husna Ibrahim, N., Yahaya, M. F., Mohamed, W., Teoh, S. L., Hui, C. K., & Kumar, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00261 · Cited by 72
Current pharmacotherapy and putative disease-modifying therapy for Alzheimer’s disease
Kulshreshtha, A., & Piplani, P. (2016) · Neurological Sciences · doi:10.1007/s10072-016-2625-7 · Cited by 86
Preclinical validation of a potent γ-secretase modulator for Alzheimer’s disease prevention
Rynearson, K. D., Ponnusamy, M., Prikhodko, O., Xie, Y., Zhang, C., Nguyen, P., Hug, B., Sawa, M., Becker, A., Spencer, B., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20202560 · Cited by 76
Targeting cancer stem cells in the clinic: Current status and perspectives
Annett, S., & Robson, T. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.02.001 · Cited by 70
Therapy for Alzheimer’s disease: Missing targets and functional markers?
Stoiljković, M., Horváth, T. L., & Hajós, M. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101318 · Cited by 78
Joshi, Y. B., & Praticò, D. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00436 · Cited by 83
“Clinical trials investigating γ-secretase inhibitors for use in AD have to date been largely unsuccessful because they are hypothesized to have altered Notch signaling as well as Aβ production (Doody et al., 2013).”
BackgroundAllosteric regulation of γ-secretase activity by a phenylimidazole-type γ-secretase modulator
Takeo, K., Tanimura, S., Shinoda, T., Osawa, S., Zahariev, I. K., Takegami, N., Ishizuka-Katsura, Y., Shinya, N., Takagi-Niidome, S., Tominaga, A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402171111 · Cited by 74
Self-citationHasegawa, M. (2016) · Biomolecules · doi:10.3390/biom6020024 · Cited by 72
“In particular, the failure of a clinical study of Aβ vaccination, immunotherapies with the antibodies, and other studies with Aβ-targeted drugs strongly suggest that the amyloid hypothesis at least does not provide a sufficient basis for development of therapeutic drugs [15–19].”
BackgroundWebster, L., Groskreutz, D., Grinbergs-Saull, A., Howard, R., O’Brien, J. T., Mountain, G., Banerjee, S., Woods, B., Perneczky, R., Lafortune, L., et al. (2017) · Health Technology Assessment · doi:10.3310/hta21260 · Cited by 74
Insights into Computational Drug Repurposing for Neurodegenerative Disease
Paranjpe, M. D., Taubes, A., & Sirota, M. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.06.003 · Cited by 70
“This need is highlighted by the consistent devastating failures of all clinical trials that have targeted canonical AD targets such as amyloid-beta[109]–[113].”
BackgroundModifying the progression of Alzheimer's and Parkinson's disease with deep brain stimulation
Jakobs, M., Lee, D. J., & Lozano, A. M. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107860 · Cited by 80
Lipids in Amyloid-β Processing, Aggregation, and Toxicity
Morgado, I., & Garvey, M. (2015) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-17344-3_3 · Cited by 71
Understanding the cause of sporadic Alzheimer’s disease
Zetterberg, H., & Mattsson, N. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.915740 · Cited by 73
“Instead, the hypothesis has been challenged by failures of several Phase III clinical trials aimed at inhibiting Ab production (secretase inhibitors) [27] or increasing its clearance from the brain (anti-Ab immunotherapy) [28,29].”
BackgroundJohnson, E. C. B., Ho, K., Yu, G.-Q., Das, M., Sanchez, P. E., Djukic, B., Lopez, I., Yu, X., Gill, M., Zhang, W., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00393-5 · Cited by 73
“Despite all the evidence suggesting a causal role of Aβ in AD, including mutations in APP and presenilin 1 and 2 that cause autosomal dominant, early-onset familial AD (FAD) and promote cerebral Aβ accumulation [4], inhibitors of BACE1 or γ-secretase have yielded negative results in clinical trials involving sporadic…”
BackgroundResultImbimbo, B. P., Ippati, S., Watling, M., & Imbimbo, C. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2022.106631 · Cited by 65
Viral Hypothesis and Antiviral Treatment in Alzheimer’s Disease
Devanand, D. P. (2018) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-018-0863-1 · Cited by 74
Revisiting the role of brain and peripheral Aβ in the pathogenesis of Alzheimer's disease
Uddin, M. S., Kabir, M. T., Tewari, D., Mamun, A. A., Mathew, B., Aleya, L., Barreto, G. E., Bin-Jumah, M. N., Abdel‐Daim, M. M., & Ashraf, G. M. (2020) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2020.116974 · Cited by 76
The Role of P2X7 Receptor in Alzheimer’s Disease
Francistiová, L., Bianchi, C., Di Lauro, C., Sebastián-Serrano, Á., de Diego-García, L., Kobolák, J., Dinnyés, A., & Díaz-Hernández, M. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00094 · Cited by 69
“One of those was focused on developing specific monoclonal antibodies against Aβ, both soluble and fibrillar forms (Doody et al., 2013; Salloway et al., 2014; Selkoe, 2019) or try to induce an active immunization.”
BackgroundCurrent and evolving treatment strategies for the Alzheimer disease continuum
(2020) · The American Journal of Managed Care · doi:10.37765/ajmc.2020.88481 · Cited by 66
Prion-like mechanisms and potential therapeutic targets in neurodegenerative disorders
Hasegawa, M., Nonaka, T., & Masuda‐Suzukake, M. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.11.010 · Cited by 76
Dysregulation of Rab5‐mediated endocytic pathways in Alzheimer's disease
Xu, W., Fang, F., Ding, J., & Wu, C. (2018) · Traffic · doi:10.1111/tra.12547 · Cited by 69
“Intraneuronal accumulation of excessive β-CTFs likely contributed to worsening cognitive function in AD patients in failed clinical trials of γ-secretase inhibitors.(16,17,73,77,78) We and others have recently demonstrated that excessive β-CTFs increased the level of activated Rab5, that is, GTPRab5, impaired retrogra…”
Have there been improvements in Alzheimer’s disease drug discovery over the past 5 years?
Cacabelos, R. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1457645 · Cited by 70
Krashia, P., Nobili, A., & D'Amelio, M. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00123 · Cited by 71
Granzotto, A., Vissel, B., & Sensi, S. L. (2024) · eLife · doi:10.7554/elife.90633 · Cited by 71
Dukart, J., Sambataro, F., Bertolino, A., & Initiative, F. T. A. D. N. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150570 · Cited by 68
Farzaei, M. H., Bahramsoltani, R., Abbasabadi, Z., Braidy, N., & Nabavi, S. M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27289 · Cited by 75
“Clinical studies on these pharmacological agents reported no significant effect on cognitive decline of patients and several adverse effects were observed (Coric et al., 2012; Doody et al., 2013).”
BackgroundAlzheimer’s disease: a review on the current trends of the effective diagnosis and therapeutics
Manap, A. S. A., Almadodi, R., Sultana, S., Sebastian, M. G., Kavani, K. S., Lyenouq, V. E., & Shankar, A. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1429211 · Cited by 84
“Semagacestat was linked to a deterioration in daily functioning and an increased incidence of infections and skin cancer (Doody et al., 2013).”
BACE2 distribution in major brain cell types and identification of novel substrates
Voytyuk, I., Mueller, S. A., Herber, J., Snellinx, A., Moechars, D., van Loo, G., Lichtenthaler, S. F., & De Strooper, B. (2018) · Life Science Alliance · doi:10.26508/lsa.201800026 · Cited by 71
Alzheimer’s disease clinical trial update 2019–2021
Pleen, J., & Townley, R. A. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10790-5 · Cited by 74
Passive immunotherapy for Alzheimer's disease
Guo, X., Li, Y., Zhang, D., & Zhao, Y. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102192 · Cited by 78
“Sem-agacestat is even associated with more skin cancer and infections (Doody et al., 2013).”
Peptides as Potential Therapeutics for Alzheimer’s Disease
Ribarič, S. (2018) · Molecules · doi:10.3390/molecules23020283 · Cited by 67
Fine‐tuning PERK signaling for neuroprotection
Halliday, M., Hughes, D., & Mallucci, G. R. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14112 · Cited by 67
Lauritzen, I., Pardossi-Piquard, R., Bourgeois, A., Bécot, A., & Checler, F. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190325092841 · Cited by 67
Alzheimer’s Disease: Combination Therapies and Clinical Trials for Combination Therapy Development
Cummings, J. L., Osse, A. M. L., Kinney, J. W., Cammann, D., & Chen, J. (2024) · CNS Drugs · doi:10.1007/s40263-024-01103-1 · Cited by 73
“…beta-site Aβ precursor protein cleaving enzyme (BACE) inhibitors could also be considered for a role in combination therapy, but these agents have toxic properties that would require further study of their biological effects and re-examining dosing strategies to ensure safe utilization [42, 43].”
Kaur, A., Mann, S., Kaur, A., Priyadarshi, N., Goyal, B., Singhal, N. K., & Goyal, D. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.03.058 · Cited by 69
“[12], avagacestat [13], LY2886721 [14], bapineuzumab [15], solanezumab [16], PBT1 and PBT2 [17] in clinical trials highlight the urgent need to identify and develop new molecules as future drug candidates for AD.”
BackgroundSelective Secretase Targeting for Alzheimer’s Disease Therapy
Miranda, A., Montiel, E., Ulrich, H., & Paz, C. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201027 · Cited by 66
A presenilin-1 mutation causes Alzheimer disease without affecting Notch signaling
Zhang, S., Cai, F., Wu, Y., Bozorgmehr, T., Wang, Z., Zhang, S., Huang, D., Guo, J., Shen, L., Rankin, C., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0101-x · Cited by 66
“the lack of efficacy or severe adverse effects at least partially associated with the inhibition of Notch signaling, such as the termination of the phase III trial of semagascestat (LY450139) [8].”
BackgroundBohm, C., Chen, F., Sevalle, J., Qamar, S., Dodd, R., Li, Y., Schmitt-Ulms, G., Fraser, P. E., & St George-Hyslop, P. H. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.02.016 · Cited by 63
“While activation of innate immune responses may initially be a protective response directed at removal of these mis-folded proteins, there is increasing evidence that chronic activation of these pathways may lead to injury of neurons via the inflammasome (Heneka et al., 2013; Tan et al., 2013).”
BackgroundMouchlis, V. D., Melagraki, G., Zacharia, L. C., & Afantitis, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030703 · Cited by 69
Hull, M., Sadowsky, C., Arai, H., Leterme, G. L. P., Holstein, A., Booth, K., Peng, Y., Yoshiyama, T., Suzuki, H., Ketter, N., et al. (2017) · Current Alzheimer Research · doi:10.2174/1567205014666170117101537 · Cited by 65
Benbow, S. J., Strovas, T. J., Darvas, M., Saxton, A., & Kraemer, B. C. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddz319 · Cited by 65
Imaging endpoints for clinical trials in Alzheimer’s disease
Cash, D. M., Rohrer, J. D., Ryan, N. S., Ourselin, S., & Fox, N. C. (2014) · Alzheimer's Research & Therapy · doi:10.1186/s13195-014-0087-9 · Cited by 62
“Semagacestat [30] 208 18 Whole brain (⇔), hippocampus (⇔)”
BackgroundInfluentialMartínková, J., Quevenco, F., Karcher, H., Ferrari, A., Sandset, E. C., Szoeke, C. E. I., Hort, J., Schmidt, R., Chadha, A. S., & Ferretti, M. T. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.24124 · Cited by 68
Metadata
- Authors
- Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., Aisen, P. S., Siemers, E., Sethuraman, G., & Mohs, R.
- Affiliations
- Baylor College of Medicine (US)
- University of California San Diego (US)
- Indiana University (US)
- The University of Tokyo (JP)
- Hôpital de La Grave (FR)
- Boston Children's Hospital (US)
- University of Rochester Medicine (US)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-07-25
- Volume
- 369
- Issue
- 4
- Pages
- 341-350
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2118935254
- Cited by
- 1,224
- References
- 24
- Citations by year
- 2026: 41 · 2025: 69 · 2024: 85 · 2023: 84 · 2022: 93 · 2021: 91 · 2020: 140 · 2019: 118 · 2018: 109 · 2017: 99 · 2016: 106 · 2015: 88 · 2014: 77 · 2013: 22
- FWCI
- 68.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (U19AG010483)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- semagacestat, Alzheimer's disease, gamma-secretase inhibitors, amyloid plaques, cognitive decline, activities of daily living, adverse events, skin cancer, lymphopenia, immunosuppression, drug safety, trial termination, dose comparison, ADAS-Cog, amyloid precursor protein, beta-secretase, gamma-secretase, treatment discontinuation
- MeSH terms
- Activities of Daily Living, Aged, Alanine, Alzheimer Disease, Azepines, Cognition, Double-Blind Method, Female, Humans, Male, Middle Aged, Skin Neoplasms, Biomarkers, Weight Loss, Amyloid beta-Peptides, Treatment Failure, Amyloid Precursor Protein Secretases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.